Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors

[Background] Gastrointestinal stromal tumor (GIST) initiation and evolution is commonly framed by KIT/PDGFRA oncogenic activation, and in later stages by the polyclonal expansion of resistant subpopulations harboring KIT secondary mutations after the onset of imatinib resistance. Thus, circulating t...

Full description

Bibliographic Details
Authors: Serrano, César, Vivancos, Ana, López-Pousa, Antonio, Matito, Judith, Mancuso, Francesco M., Valverde, Claudia M., Quiroga, Sergi, Landolfi, Stefania, Castro, Sandra, Dopazo, Cristina, Sebio, Ana, Virgili, Anna C., Menso, María M., Martín-Broto, Javier, Sansó, Miriam, García-Valverde, Alfonso, Rosell, Jordi, Fletcher, Jonathan A., George, Suzanne, Carles, Joan, Arribas, Joaquín
Format: article
Publication Date:2020
Country:España
Institution:Consejo Superior de Investigaciones Científicas (CSIC)
Repository:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/236485
Online Access:http://hdl.handle.net/10261/236485
Access Level:Open access
Keyword:Circulating tumor DNA
Gastrointestinal stromal tumor
Imatinib
KIT
Liquid biopsy
PDGFRA
Sarcoma
Regorafenib
Sunitinib
Description
Summary:[Background] Gastrointestinal stromal tumor (GIST) initiation and evolution is commonly framed by KIT/PDGFRA oncogenic activation, and in later stages by the polyclonal expansion of resistant subpopulations harboring KIT secondary mutations after the onset of imatinib resistance. Thus, circulating tumor (ct)DNA determination is expected to be an informative non-invasive dynamic biomarker in GIST patients.

Similar Items